Investment

Revel Pharmaceuticals’ seed round for anti-aging drugs

Top Yale lab spawns new company focused on development of glucosepane-cleaving drugs. San Francisco based biotech start-up Revel Pharmaceuticals has announced itself to the...

Evolution 2.0 prize: The $10 million question

Major new prize announced to help identify how cells intentionally self-organise and communicate; George Church part of judging panel. The origin of life is often...

Longevity stocks: Stay private longer?

Going public as a Longevity stock is all about good timing and good clinical results: Some stand-out performers have experienced a volatile year. The world’s...

NeoGenomics acquires Human Longevity’s oncology tech

Acquisition of Human Longevity’s oncology division for $37m demonstrates both the opportunities and challenges for Longevity investing. On Friday, NeoGenomics announced that it had agreed...

Latest articles

Insurer puts down £20m to research an aging rethink

A new partnership between Legal & General and Edinburgh University aims to address the societal and economic implications of an aging society. The world is...

23andMe redundancies: DNA test market decline?

Could layoffs at 23andMe be a sign that the consumer appetite for genetic testing is declining? We expect consumer markets to transition to more...

Singapore agetech – ones to watch in 2020

Singapore thrives on its prime location at the crossroads of Asia's biggest markets, low business tax and great IT infrastructure; it is well-positioned to...

Innovating organ-on-chip to accelerate research

BIOFABICS brings custom design tools to biofabrication. While still in its infancy, organ-on-chip (OOC) technology is quickly becoming a key growth segment in the Longevity...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.